SCHEMBL13624233

SCHEMBL13624233

CC[C@H](N)CNc1ccc(N2CCSCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 2/20 0.39
MAPT P10636 8/20 0.38
ALDH1A1 P00352 6/20 0.38
GAA P10253 7/20 0.37
ALOX15 P16050 4/20 0.37
ALOX12 P18054 4/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
NPC1 O15118 3/20 0.37
TP53 P04637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 5/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
MAPK1 P28482 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
APP P05067 1/20 0.36
SNCA P37840 1/20 0.36
SPHK1 Q9NYA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377745 0.85 SMN1; SMN2 (0.50) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL4377743 0.85 SMN1; SMN2 (0.50) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL4368258 0.84 GAA (0.52) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL4368253 0.84 GAA (0.52) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL13624230 0.77 LGMN (0.38) LGMNALDH1A1
SCHEMBL13624236 0.75 MAPT (0.51) MAPTRAB9AKMT2ASPHK1
SCHEMBL13624231 0.73 MAPT (0.56) LGMNMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL13624235 0.72 KMT2A (0.38) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL13624239 0.71 ALDH1A1 (0.46) MAPTALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL26436977 0.71 MAPT (0.45) MAPTALDH1A1GAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS CTSE, SPINT2, CTSF LGMN 585/4885MAPT 480/4885ALDH1A1 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.